E

Epizyme Inc
F:EPE

Watchlist Manager
Epizyme Inc
F:EPE
Watchlist
Price: 559 EUR 3.33% Market Closed
Market Cap: 92.2B EUR

EV/FCFF
Enterprise Value to FCFF

-513.4
Current
-486
Median
3.6
Industry
Lower than median
Lower than industry value

Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

EV/FCFF
-513.4
=
Enterprise Value
94.2B EUR
/
FCFF
-208.9m USD
 
US
E
Epizyme Inc
F:EPE
Average EV/FCFF: 24.2
Negative Multiple: -513.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 472.3
US
Abbvie Inc
NYSE:ABBV
25.5
US
Amgen Inc
NASDAQ:AMGN
18.4
US
Gilead Sciences Inc
NASDAQ:GILD
15.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -86.4
AU
CSL Ltd
ASX:CSL
45.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -62.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -508.2
NL
argenx SE
XBRU:ARGX
Negative Multiple: -208.1

EV/FCFF Forward Multiples

Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A